Updated recommendations for the use of typhoid vaccine — advisory committee on immunization practices, United States, 2015

Morbidity and Mortality Weekly Report

Volumn 64, Issue 11, 2015, Pages 305-308

  Jackson, Brendan R ^a   Iqbal, Shahed ^a   Mahon, Barbara ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHOID PARATYPHOID VACCINE;

ADVISORY COMMITTEE; HUMAN; IMMUNIZATION; PRACTICE GUIDELINE; TYPHOID FEVER; UNITED STATES;

ADVISORY COMMITTEES; HUMANS; IMMUNIZATION SCHEDULE; PRACTICE GUIDELINES AS TOPIC; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; UNITED STATES;

EID: 84929515056     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. CDC. Typhoid immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1994;43(No. RR-14).
2. CDC. CDC health information for international travel 2014. Available at http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014.
3. Stuart BM, Pullen RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic) 1946;78:629–61.
4. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005;366:749–62.
5. CDC. National Typhoid and Paratyphoid Fever Surveillance. Available at http://www.cdc.gov/nationalsurveillance/typhoid-surveillance.html.
6. Steinberg EB, Bishop R, Haber P, et al. Typhoid fever in travelers: who should be targeted for prevention? Clin Infect Dis 2004;39:186–91.
7. Johnson KJ, Gallagher NM, Mintz ED, Newton AE, Brunette GW, Kozarsky PE. From the CDC: new country-specific recommendations for pre-travel typhoid vaccination. J Travel Med 2011;18:430–3.
8. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010;50:241–6.
9. Maskey A P, Day JN, Phung QT, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006;42:1247–53.
10. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007;45(Suppl 1):S24–8.
11. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009;16:46–52.
12. Gilman RH, Hornick RB, Woodard WE, et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis 1977;136:717–23.
13. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2014; 1:CD001261.
14. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335–44.
15. Khan MI, Soofi SB, Ochiai RL, et al.; DOMI Typhoid Karachi Vi Effectiveness Study Group. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012;30:5389–95.
16. Mahon BE, Newton AE, Mintz ED. Effectiveness of typhoid vaccination in US travelers. Vaccine 2014;32:3577–9.
17. Lin FYC, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001;344:1263–9.
18. Szu SC. Development of Vi conjugate — a new generation of typhoid vaccine. Expert Rev Vaccines 2013;12:1273–86.
19. Bacaner N, Stauffer B, Boulware DR, Walker P F, Keystone JS. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004;291:2856–64.
20. Typhim Vi Polysaccharide Vaccine [package insert]. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM142811.pdf.
21. Vivotif Typhoid Vaccine Live Oral Ty21a [package insert]. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM142807.pdf.
22. Marcus LC, Froeschle JE, Hill DR, et al. Safety of Typhim Vi vaccine in a postmarketing observational study. J Travel Med 2007;14:386–91.
23. Begier EM, Burwen DR, Haber P, Ball R; Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis 2004;38:771–9.
24. Simanjuntak CH, Paleologo F P, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055–9.
25. Levine MM, Black RE, Ferreccio C, et al. The efficacy of attenuated Salmonella typhi oral vaccine strain Ty21a evaluated in controlled field trials. In: Development of vaccines and drugs against diarrhea. 11th Noble Conference, Stockholm, 1985. Holmgren J, Lindberg A, Mollby R (eds). Lund, Sweden: Studentlitteratur; 1986:90–101.
26. National Center for Immunization and Respiratory Diseases. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-2):1–64.
27. Vivotif typhoid vaccine oral attenuated Ty21a [product monograph]. Available at http://www.crucellvaccinescanada.com/pdf/vivotif_pm.pdf.